Metoclopramid Basi (Metoclopramide Hydrochloride Anhydrous)

Metoclopramide blocks dopamine D2 receptors in the brain’s chemoreceptor trigger zone, reducing the signal that initiates nausea and vomiting. In the gastrointestinal tract, it enhances acetylcholine release, which increases smooth‑muscle contractions, thereby accelerating gastric emptying and improving overall gut motility.

The specific dose of Metoclopramid Basi is determined by the prescribing clinician based on the patient’s condition, age, weight, and renal or hepatic function. Healthcare professionals tailor the regimen to achieve optimal therapeutic effect while minimizing potential adverse reactions.

The safety of metoclopramide in pregnancy has not been definitively established, and its pregnancy category is listed as unknown. It should only be used when the potential benefit justifies any possible risk to the fetus. Limited data suggest it may be excreted in breast milk, so a risk‑benefit assessment is required for nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and assistance with import documentation.

Metoclopramide differs from other antiemetics such as 5‑HT3 antagonists (e.g., ondansetron) by targeting dopamine receptors and also acting as a gastroprokinetic. This dual action makes it useful for both nausea control and enhancing gastric emptying, whereas some alternatives focus solely on the emetic pathway without affecting motility.

Metoclopramid Basi should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain its stability and potency.

The medication is supplied as an injectable solution and can be given either intramuscularly or intravenously. Administration technique, rate, and site are determined by the healthcare professional according to the clinical indication and patient-specific factors.

Serious risks include tardive dyskinesia, a potentially irreversible movement disorder, neuroleptic malignant syndrome, severe allergic reactions, and seizures. Patients should be monitored closely for any signs of these conditions, and therapy should be discontinued immediately if they occur.

Metoclopramid Basi is contraindicated in individuals with known hypersensitivity to metoclopramide or any of its excipients, and it should be avoided in patients with a history of seizure disorders, severe depression, or those taking monoamine oxidase inhibitors. Caution is also advised for patients with gastrointestinal obstruction or perforation.